Drugs / Corfluvec component 1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05696067 | Sep → Dec 2022 | COVID-19 | Tatyana Zubkova | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Corfluvec component 1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05696067 ↗ |
| Modality | Vaccine | “two-component intranasal vaccine for the prevention of COVID-19” NCT05696067 ↗ |
| Route | Intranasal | “Participants will receive single intranasal injection of H3N2 recombinant attenuated influenza vector” NCT05696067 ↗ |